Protocols
11 protocol(s) meet the specified criteria
Disease Site: Leukemia, other
Protocol No.TitleStatus
AALL1631International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones.Open
BMT-CTN-1506A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AMLOpen
EAI141Early Assessment of Treatment Response in AML using FLT PET/CT ImagingOpen
INCB-18424-365A Phase III Randomized Open-Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease After Allogenic Stem Cell Transplantation (REACH 3)Open
J1651Phase 2 Study of Azacitidine (AZA) in Combination with Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (>65 Years) AML PatientsOpen
LCCC0824Tissue Procurement For Hematolymphoid ConditionsOpen
LCCC0905Graft-Versus-Host Disease Solid Tissue ProcurementOpen
LCCC1241Complementary and Alternative medicine use at UNC clinicsOpen
LCCC1726Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell TransplantationOpen
LCCC1805Pediatric Oncology Tissue Procurement to Support Research on Molecular Drivers and Precision Medicine ApproachesOpen
M16-106/ABBVIEA Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination with Navitoclax and Chemotherapy in Subjects with Relapsed Acute Lymphoblastic LeukemiaOpen